Author Correction : An investigation into the mechanism of nobiletin's inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology
Correction to: European Review for Medical and Pharmacological Sciences 2023; 27 (4): 1553-1564. DOI: 10.26355/eurrev_202302_31398-PMID: 36876711-published online on February 15, 2023. After publication, the authors applied some corrections to the galley proof: - The order of Table I and II has been inverted. - The scale bar of Figure 9A has been inserted in the Legend. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/31398.
| Errataetall: |
ErratumFor: Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1553-1564. - PMID 36876711 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
European review for medical and pharmacological sciences - 27(2023), 7 vom: 23. Apr., Seite 2715 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Q-J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.04.2023 Date Revised 25.04.2024 published: Print ErratumFor: Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1553-1564. - PMID 36876711 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.26355/eurrev_202304_31896 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355747766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355747766 | ||
| 003 | DE-627 | ||
| 005 | 20240426233153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26355/eurrev_202304_31896 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM355747766 | ||
| 035 | |a (NLM)37070868 | ||
| 035 | |a (PII)31896 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Q-J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Author Correction |b An investigation into the mechanism of nobiletin's inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2023 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumFor: Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1553-1564. - PMID 36876711 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Correction to: European Review for Medical and Pharmacological Sciences 2023; 27 (4): 1553-1564. DOI: 10.26355/eurrev_202302_31398-PMID: 36876711-published online on February 15, 2023. After publication, the authors applied some corrections to the galley proof: - The order of Table I and II has been inverted. - The scale bar of Figure 9A has been inserted in the Legend. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/31398 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Li, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, R-H |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, H |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, W-J |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, J-J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 27(2023), 7 vom: 23. Apr., Seite 2715 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:7 |g day:23 |g month:04 |g pages:2715 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202304_31896 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 7 |b 23 |c 04 |h 2715 | ||